3-D Matrix, Ltd. Stock

Equities

7777

JP3410730000

Biotechnology & Medical Research

Market Closed - Japan Exchange 02:00:00 2024-06-28 am EDT 5-day change 1st Jan Change
140 JPY +1.45% Intraday chart for 3-D Matrix, Ltd. +12.90% 0.00%
Sales 2022 1.51B 9.36M Sales 2023 2.31B 14.38M Capitalization 9.97B 61.93M
Net income 2022 -1.89B -11.77M Net income 2023 -2.44B -15.19M EV / Sales 2022 13.1 x
Net Debt 2022 817M 5.08M Net Debt 2023 3.2B 19.9M EV / Sales 2023 5.69 x
P/E ratio 2022
-9.3 x
P/E ratio 2023
-3.87 x
Employees 108
Yield 2022 *
-
Yield 2023
-
Free-Float 92.11%
More Fundamentals * Assessed data
Dynamic Chart
3-D Matrix, Ltd. announced that it has received ¥22.62 million in funding from CVI Investments, Inc. CI
3-D Matrix, Ltd. announced that it expects to receive ¥22.62 million in funding from CVI Investments, Inc. CI
3-D Matrix, Ltd.(TSE:7777) dropped from S&P Global BMI Index CI
3-D Matrix, Ltd. announced that it has received ¥686.237876 million in funding from CVI Investments, Inc. CI
3-D Matrix, Ltd. announced that it expects to receive ¥686.237876 million in funding from CVI Investments, Inc. CI
3-D Matrix, Ltd. announced that it has received ¥508.76 million in funding from CVI Investments, Inc. CI
3-D Matrix, Ltd. announced that it expects to receive ¥508.76 million in funding from CVI Investments, Inc. CI
3-D Matrix, Ltd. announced that it has received ¥2.059835568 billion in funding from CVI Investments, Inc. CI
3-D Matrix, Ltd. announced that it expects to receive Ñ2.059835568 billion in funding from CVI Investments, Inc. CI
3-D Matrix, Ltd. Auditor Raises 'Going Concern' Doubt CI
3-D Matrix, Ltd. announced that it has received ¥1.77192847 billion in funding from CVI Investments, Inc. CI
3-D Matrix, Ltd. announced that it expects to receive ¥1.77192847 billion in funding from CVI Investments, Inc. CI
3-D Matrix, Ltd. announced that it has received ¥2.609 billion in funding from CVI Investments, Inc. CI
3-D Matrix, Ltd. announced that it expects to receive ¥2.609 billion in funding from CVI Investments, Inc. CI
3-D Matrix, Ltd. signed contract to acquire 10% stake in PURMX Therapeutics Co., Ltd. CI
More news
1 day+1.45%
1 week+12.90%
Current month+1.45%
3 months+12.90%
6 months-2.78%
More quotes
1 week
125.00
Extreme 125
146.00
1 month
124.00
Extreme 124
169.00
Current year
101.00
Extreme 101
169.00
1 year
101.00
Extreme 101
186.00
3 years
101.00
Extreme 101
643.00
5 years
101.00
Extreme 101
679.00
10 years
101.00
Extreme 101
4 345.00
More quotes
Managers TitleAgeSince
Director of Finance/CFO 51 08-11-30
President 49 05-07-31
Director/Board Member 47 19-06-30
Members of the board TitleAgeSince
Director/Board Member 51 08-06-30
President 49 05-07-31
Chairman 70 04-05-18
More insiders
Date Price Change Volume
24-06-28 140 +1.45% 631,900
24-06-27 138 +6.15% 2,055,900
24-06-26 130 +1.56% 742,200
24-06-25 128 0.00% 357,500
24-06-24 128 +3.23% 518,600

Delayed Quote Japan Exchange, June 28, 2024 at 02:00 am EDT

More quotes
3-D Matrix, Ltd. is a company engaged in the research, development, manufacture and sale of medical products. The Company has Medical Product segment. The segment consists of two divisions. The medical product development and sales division is engaged in the research and development of medical equipment and drugs for surgery area, regeneration medicine area and drug delivery system (DDS) area based on the self-organizing peptide technology, including hemostatic, vascular embolization and alveolar bone reconstruction materials, among others. The research reagents sales division is engaged in the sale of medical products based on the self-organizing peptide technology for research and test use in universities and research institutes.
More about the company